Truck driver Theron Schmalzried describes the delivery journey on ‘Fox & Friends.’
Truck driver Theron Schmalzried describes the delivery journey on ‘Fox & Friends.’
Television director Tristram Shapeero is taking responsibility for his comment during a virtual audition that was recently shared by "Euphoria" actor Lukas Gage. In the video clip, which went viral earlier in the week, Shapeero can be heard saying, "These poor people live in these tiny apartments. Like I'm looking at his, you know, background […]
Turkey protested to Germany and the EU on Monday after German forces belonging to an EU military mission boarded and tried to search a Turkish cargo ship that they suspected of taking weapons to Libya illegally. Soldiers from the frigate Hamburg, part of an EU mission enforcing a UN arms embargo, boarded the Roseline A overnight but withdrew after Turkey raised objections with the EU mission, which had ordered the search, the German Defence Ministry said.Turkey released footage showing armed men in military uniform marshalling sailors with their hands on their heads on the bridge of what it said was the Roseline A, at sea southwest of the Greek Peloponnese peninsula.Germany’s Defense Ministry said Turkey ordered a halt to the search, forcing the German personnel to depart before completing their work. During their search, the German team had found no cargo that contravened the arms embargo, German Defense Ministry spokesman Christian Thiels told reporters in Berlin. This was the second incident between Turkey and naval forces from a NATO ally country enforcing an arms blockade against Libya. In June, NATO launched an investigation over an incident between Turkish warships and a French naval vessel in the Mediterranean, after France said one of its frigates was “lit up” three times by Turkish naval targeting radar when it tried to approach a Turkish civilian ship suspected of involvement in arms trafficking.Search ends after 'persistent objections'The Turkish Foreign Ministry said the German warship’s personnel conducted the search despite the captain's statements about what his ship was carrying. The search ended after Turkey's “persistent objections," it said. “We protest this act which was unauthorised and conducted by force,” Turkish Foreign Ministry spokesman Hami Aksoy said in a statement. He added that Turkey may seek compensation for damage or losses.Aksoy renewed Turkey's criticism of the Rome-headquartered EU naval mission which aims to halt arm shipments to Libya and which Ankara has accused of favouring Libya's eastern-based forces against the Tripoli-based Government of National Accord.Turkish Deputy Foreign Minister Sedat Onel later summoned the Italian ambassador, the German Embassy's Charge d' Affaires as well as the EU's envoy to Turkey to formally protest the incident, the ministry said. 'Biscuits and other material such as paints'A senior official said the German team terminated its search aboard the Rosaline-A around dawn after “understanding that there was nothing but humanitarian aid, biscuits and other material such as paints on board.” The freighter continued on its way to Misrata after the search, the official said, speaking on condition of anonymity in line with Turkish government rules. Thiels, the German Defense Ministry spokesman, said the German crew requested permission to board. “Upon receiving no reply, a German search team was brought by helicopter to the freighter and commenced the search, and the crew was ‘cooperative',” Thiels said.While the team continued its search, German authorities were notified by Turkey that they were disallowing it. The search was then ended and the team sent back to the frigate, Thiels said.The German official said the order to board the ship came from mission's operational headquarters in Rome.(FRANCE 24 with AP and REUTERS)
India coach Ravi Shastri acknowledged his team lack Australia's pink-ball experience but is convinced their "fabulous five" pacemen can bowl the tourists to a second successive test series victory Down Under. Australia have played seven day-night tests, the most by any country, since 2015 and won each of them. India were late to embrace the innovation and played their only pink-ball test against Bangladesh in Kolkata last year.
On Monday night, Jimmy Kimmel took aim at one of his favorite comedic targets: Donald Trump, Jr., the ne’er-do-well eldest son of outgoing President Trump. In the past, Kimmel has called out the extremely-online heir for spreading wacky conspiracy theories and overall idiocy, leading the two to lob insults at each other on Twitter and the Trump spawn to resurface old comedy sketches of Kimmel’s that he objects to in an attempt to “cancel” him, while at the same time whining incessantly about so-called “cancel culture.” So you just knew that Kimmel would address Don Jr. coming down with COVID-19 this past week—a disease that his accused sexual harasser-girlfriend Kimberly Guilfoyle and accused serial rapist-father have also contracted.“There are more new COVID cases in Trumpsylvania. Andrew Giuliani, son of Rudy and a special assistant to the president, has COVID, and this guy’s got it too,” offered Kimmel during his monologue. He then threw to a clip Don Jr. posted to Instagram of himself announcing, “You may have seen it by now, but, uh, apparently I got the ‘rona.” “Apparently I got the ‘rona,” mimicked Kimmel, before joking, “Why do bad things keep happening to good people? I just don’t [know]. If you refer to it as ‘the ‘rona,’ you might not deserve to get the virus, but you deserve to get it more than anybody else does.”‘Veep’ Creator Armando Iannucci: There’s Nothing Funny About ‘Gollum’ TrumpLater on, he poked fun at Donald Trump, Jr. for repeatedly downplaying COVID-19, with the Trump heir saying last month on Fox News that the number of dead from COVID-19 was “almost nothing.” (1,952 Americans died on Friday from COVID-19, and close to 260,000 Americans have passed away from the disease thus far.)“DJTJ will isolate for 14 days on his favorite stump,” joked Kimmel, throwing to the memeified photo of Don Jr. in the woods alone, awkwardly sitting on a tree stump and staring off into the distance. “You ever read the book The Giving Tree? Well, that terrible boy has come to life. It’s interesting that Donnie J got it, because just last month he said that the number of COVID cases was ‘almost nothing’—which also happens to be the title of his autobiography: Almost Nothing.”Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.
Save on a wide range of UPPAbaby VISTA and more baby deals at the Black Friday sale, together with the top UPPAbaby VISTA V2, CRUZ, MINU & MESA offers
Bitcoin investors, which include top hedge funds and money managers, are betting the virtual currency could more than quintuple to as high as $100,000 in a year. Bitcoin is within sight of its all-time peak of just under $20,000 hit in December 2017. Going from $18,000 to $100,000 in one year is not a stretch, Brian Estes, chief investment officer at hedge fund Off the Chain Capital, said.
Activist hedge fund Elliott Management Corp has invested at least $30 million in Cataleya Energy, a small firm focused on oil exploration in Guyana, the world's newest oil and gas hot spot, two people familiar with the matter said. The deal reflects rising interest in Guyana, a small South American country of 750,000 whose oil discoveries are set to transform an economy dependent on agriculture and mining. Five years ago, a consortium led by Exxon Mobil Corp struck oil off the Guyanese coast in the 6.6 million-acre (26,800 square kilometer) Stabroek block that has been shown to hold more than 8 billion barrels of recoverable oil and gas.
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study results24.11.2020 / 07:12 NeuroRx and Relief announce initial successful results from expanded access use of RLF-100(TM) (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patientsGeneva, Switzerland and Radnor, PA, November 24, 2020 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc., announced that more than 175 patients with Critical COVID-19 and Respiratory Failure who also have a severe comorbidity have now been entered into an Expanded Access Protocol (EAP) with RLF-100(TM) in the United States.All patients had severe comorbidities (such as organ transplant, recent heart attack, and cancer) that rendered them ineligible for the ongoing randomized, controlled phase 2b/3 trial being conducted to ascertain safety and efficacy of RLF-100(TM), and all patients were deteriorating despite treatment with approved therapies for COVID-19 (see www.clinicaltrials.gov NCT 04311697). Of the 90 patients who have so far reached 28 days of follow-up, 72% survived to day 28.As previously reported by Youssef and coworkers (http://dx.doi.org/10.2139/ssrn.3665228), at Houston Methodist Hospital, 21 patients treated with RLF-100(TM) under the EAP were compared to 24 control patients treated in the same setting. Only 17% of the control patients, all treated with best available intensive care unit (ICU) Standard of Care, survived to day 28. The survival rate with RLF-100(TM) reported today is comparable to that seen among the open-label patients treated with RLF-100(TM) by Youssef et al. Despite advancements in treating COVID-19, survival for the patients at highest risk due to severe comorbidities has remained dismal in the absence of an effective therapy.Notably, in the EAP, no drug-related Serious Adverse Events have been reported to date among these patients nor the 160 patients randomized to RLF-100(TM) vs. placebo in the U.S. phase 2b/3 clinical trial currently underway. Thus, from a risk/benefit perspective, while the benefit of RLF-100(TM) has not yet been proven in a randomized prospective trial, no serious risk has been identified so far.Currently, 25 U.S. hospitals have enrolled patients in the EAP, nearly all of which are community hospitals, suggesting that RLF-100(TM) can demonstrate effectiveness in the hands of front-line physicians who deliver the majority of care to patients with Critical COVID-19. Physicians enrolling patients in the EAP have routinely reported that initial patients at their sites have frequently been in the ICU for several weeks without recovery prior to treatment with RLF-100(TM). As patients are treated earlier in the course of their ICU stay, there is an emerging clinical impression that RLF-100(TM) has an even greater impact on recovery."We are reassured that emerging real-world data on the use of RLF-100(TM) in improving survival in patients with Critical COVID-19 are comparable to results seen in the hands of major academic teaching centers. We hope that these findings are viewed as encouraging at a time when many Americans, including the doctors, nurses, and other front-line caregivers who are the heart of our initiative, are celebrating the Thanksgiving holiday at a distance from their loved ones. We look forward to completing enrollment and reporting the results of our pivotal U.S. clinical trial," said Prof. Jonathan C. Javitt, MD, MPH, CEO and founder of NeuroRx, Inc.###ABOUT VIP IN LUNG INJURYVasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the alveolar type 2 cell, that is critical to transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.COVID-19-related death is primarily caused by respiratory failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and are essential for oxygen exchange. Other than RLF-100(TM), no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.ABOUT RLF-100(TM)RLF-100(TM) (Aviptadil) is a formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Sami Said's original work at Stony Brook University, for which Stony Brook was awarded an FDA Orphan Drug Designation in 2001. VIP is known to be highly concentrated in the lungs, where it inhibits coronavirus replication, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant. FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100(TM) for the treatment of COVID-19 and awarded Fast Track designation. RLF-100(TM) is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, more than 150 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100(TM) under FDA-approved protocols. Information on the RLF-100(TM) Expanded Access program is at https://www.neurorxpharma.com/our-services/rlf-100.ABOUT RELIEF THERAPEUTICS HOLDING AGRelief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the U.S. and multiple other countries covering potential formulations of RLF-100(TM).RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on the OTCQB under the symbol RLFTF.ABOUT NEURORX INC.NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100(TM), NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. The results reported herein may or may not be indicative of the results of future and larger clinical trials for RLF-100(TM) for the treatment of COVID-19. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. CORPORATE CONTACT RELIEF THERAPEUTICS Holding AG Raghuram (Ram) Selvaraju, Ph.D., MBA Chairman of the Board Mail: firstname.lastname@example.org www.relieftherapeutics.com NeuroRx, Inc. Jonathan C. Javitt, M.D., MPH Chairman and Chief Executive Officer Mail: email@example.com MEDIA CONTACT: Relief (Europe) MC Services AG Anne Hennecke / Brittney Sojeva Tel.: +49 (0) 211-529-252-14 Mail: firstname.lastname@example.org NeuroRx (United States) David Schull Russo Partners, LLC Tel.: +1 (0) 858-717-2310 Mail: email@example.com INVESTOR RELATIONS Relief (Europe) MC Services AG Anne Hennecke / Brittney Sojeva Tel.: +49 (0) 211-529-252-14 Mail: firstname.lastname@example.org NeuroRx (United States) Brian Korb Solebury Trout Tel.: +1 (0) 917-653-5122 Mail: email@example.com End of Media Release Language: English Company: RELIEF THERAPEUTICS Holdings AG Avenue de Sécheron 15 1202 Genève Switzerland E-mail: firstname.lastname@example.org Internet: https://relieftherapeutics.com ISIN: CH0100191136 Listed: SIX Swiss Exchange EQS News ID: 1150117 End of News EQS Group News Service
Black Friday AV receiver deals have landed, browse the best Black Friday Onkyo, Denon, Harman & Kardon, Marantz & Yamaha deals on this page
When Kuwait emerged from a monthslong coronavirus lockdown, hundreds of Kuwaitis flocked to reopened stores, the lines clogging malls, snaking through hallways and spilling onto sidewalks. The jewelry-store rush by Kuwait's long-coddled citizens is a symptom of a looming disaster. Kuwait, one of the world’s wealthiest countries, is facing a debt crisis.
Donald Trump has accepted that a formal transition can begin for Joe Biden to take office. Mr Biden was declared the “apparent winner” of the US election by a key federal agency, clearing the way for the start of the transition. A federal official said the determination was made after Mr Trump's efforts to subvert the vote failed across battleground states, most recently in Michigan.
President has finally admitted a transition process must begin, but still vows to continue his legal battles
Black Friday trampoline deals are underway, check out all the best Black Friday square, rectangle, and round trampoline savings here on this page
David Dinkins, who broke barriers as New York City’s first African-American mayor, but was doomed to a single term by a soaring murder rate, stubborn unemployment and his mishandling of a race riot in Brooklyn, has died. Dinkins died Monday, the New York City Police Department confirmed. Dinkins, a calm and courtly figure with a penchant for tennis and formal wear, was a dramatic shift from both his predecessor, Ed Koch, and his successor, Rudolph Giuliani — two combative and often abrasive politicians in a city with a world-class reputation for impatience and rudeness.
A new round of social distancing rules took effect on Tuesday in the South Korean capital of Seoul, dealing a blow to small business owners despite brighter hopes for economic recovery after earlier success in battling the coronavirus. The Korea Disease Control and Prevention Agency (KDCA) reported 349 cases, as the daily tally ticked up again after a slight drop reflecting fewer weekend tests.
DGAP-News: Brockhaus Capital Management AG / Key word(s): 9 Month figures24.11.2020 / 07:01 The issuer is solely responsible for the content of this announcement.BCM AG (nine-month report): Despite corona stable margin above 20% with significant increase in order intake- BCM Group generates revenue of € 33.9 million in the first nine months of financial year 2020; decline of -16% compared to (pro forma) previous year's period - Adjusted EBITDA margin remains stable above 20% as in H1 2020 - Significant increase in group order intake Q3 2020 of +24% compared to Q2 2020- Capital increase from the listing fully available for acquistions; total cash of € 122 millionFrankfurt/Main, November 24, 2020. Brockhaus Capital Management AG (BKHT, ISIN: DE000A2GSU42, "BCM"), a long-term oriented technology group focused on acquiring high-margin and high-growth technology champions within the German Mittelstand, published its nine-month figures for the financial year 2020.In the first nine months of financial year 2020, BCM Group generated revenue of € 33.9 million. This represents a decline of -16% compared with the previous pro forma reporting period 9M 2019. The reason for this was the COVID-19-related revenue decline of the Security Technologies segment. In the Environmental Technologies segment, however, BCM Group continued to increase revenue significantly. Nevertheless, given its smaller absolute size compared with the Security Technologies segment, it could not fully compensate the decline in business. On a non-pro forma basis, i.e. including inorganic growth through acquisitions, revenue grew by +290.4% compared with the same period of the previous year. With an adjusted EBITDA of € 7.0 million, BCM has also kept the margin constantly above 20% as in H1 2020. In addition, order intake of BCM Group increased significantly by +24% in the third quarter, as compared with Q2 2020.As of the reporting date, cash amounted to approximately € 122 million. On this solid basis, BCM Group believes it is well equipped to respond flexibly to attractive acquisition opportunities.Revenue in Environmental Technologies segment grows by +17%; continued strong demand with a massive increase in order intake compared with 9M 2019In the Environmental Technologies segment - consisting of Palas - revenue in the first nine months increased by +17.3% despite the COVID-19 pandemic. Although the first quarter was comparably weak due to general revenue fluctuations between the quarters and the initial effects of the lockdowns, customer demand grew significantly in the second and third quarters. The COVID-19 pandemic has brought aerosols (particles in air) into the center of public attention and Palas has successfully positioned itself as a technology leader with its aerosol measurement technology. Especially test rigs for the effectiveness control of respiratory masks continued to sell particularly well. Other products related to aerosole measurement, for instance indoor or exhalation measurement, have followed or will follow. Order intake in the reporting period was massively above the same period of the previous year 9M 2019.In addition, on August 27, 2020 Palas filed a patent with the European Patent Office for a measurement device for the immediate detection of particle number and size in exhaled air. The universally applicable measurement device developed by Palas can immediately identify particles in exhaled air with high-precision size resolution and could thus help to detect infectivity in human beings. This could in particular contribute to the containment of the current COVID-19 pandemic. The patent application has not yet been disclosed. A patent application is generally published 18 months from the filing date and the patentee is only entitled to rights from the patent application after this period.Significant increase in order intake in the Security Technologies segment, despite COVID-19 related project postponementsThe Security Technologies segment recorded a decline in revenue of -25.1% in 9M 2020. After revenue in the first quarter was substantially higher than in the same period of the previous year, the development deteriorated significantly in the second quarter, a trend that continued in the third quarter in terms of revenue. Key projects were delayed due to global lockdown measures as well as travel bans and social distancing restrictions. This effect was intensified in the third quarter of 2020 by the comparison to the very successful Q3 2019, which had marked by far the strongest quarter in terms of revenue in the previous fiscal year and in the company's entire history. In terms of order intake, however, the third quarter of 2020 showed a considerable recovery with a significant increase compared to Q2 2020.As previously announced in the ad-hoc release of November 13, 2020, BCM Group expects a single-digit percentage decline in revenue for the 2020 financial year compared with the (pro forma) revenue of € 54.3 million in the previous year 2019. However, given the "mission critical" nature of its technologies, BCM Group expects significant catch-up effects in the following year 2021, subject to the continuing uncertainties regarding the course, duration and impact of the COVID-19 pandemic on global economic development.The quarterly report 9M 2020 is now available at https://ir.bcm-ag.com/publications.html. Financial CalendarApril 15, 2021 Annual Report 2020May 15, 2021 Quarterly Report Q1 2021June 16, 2021 Annual General Meeting 2021 About Brockhaus Capital ManagementBrockhaus Capital Management AG (BKHT, ISIN: DE000A2GSU42, "BCM"), based in Frankfurt/Main, is a technology group acquiring high-margin and high-growth technology champions with B2B business models in the German Mittelstand. With a unique platform approach and a long-term horizon, BCM actively and strategically supports its subsidiaries in achieving long-term profitable growth beyond industry and country boundaries. At the same time, BCM offers a gateway into these non-listed German technology champions, which are otherwise inaccessible to capital market investors.Contact DetailsFor investors:Brockhaus Capital ManagementPaul GöhringHead of Investor RelationsPhone: +49 69 20 43 40 978Fax: +49 69 20 43 40 971E-Mail: email@example.comFor media: USCIris C. SistemichPhone: +49 221 280 655 10E-Mail: firstname.lastname@example.org Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Brockhaus Capital Management AG Thurn-und-Taxis-Platz 6 60313 Frankfurt am Main Germany Phone: +49 (0)69 2043 409 0 Fax: +49 (0)69 2043 409 71 E-mail: email@example.com Internet: http://bcm-ag.com ISIN: DE000A2GSU42 WKN: A2GSU4 Listed: Regulated Market in Frankfurt (Prime Standard) EQS News ID: 1150121 End of News DGAP News Service
While all eyes have been on Boko Haram in Nigeria northeast, the northwest of the country has also been unraveling spiking food insecurity risk
'Orwellian' government unit obstructs freedom of information, says report. ‘Clearing house’ requires Whitehall departments to send it sensitive requests for vetting
TV tonight: mystery and angst in Luca Guadagnino's coming-of-age dramaTeenager Fraser arrives in Italy and struggles to fit in with his peers on a US army base. Plus: the Bake Off finalists wrestle with puff pastry and towering desserts. Here’s what to watch this evening
Croydon council outlines drastic cuts to jobs and services. Council, which in effect declared insolvency this month, said it would adopt a bare legal minimum approach